Genprex, Inc. (NASDAQ:GNPX) Short Interest Update

Genprex, Inc. (NASDAQ:GNPX) saw a significant decline in short interest in the month of March. As of March 31st, there was short interest totalling 277,400 shares, a decline of 16.8% from the March 15th total of 333,600 shares. Approximately 1.2% of the company’s shares are sold short. Based on an average trading volume of 3,800,000 shares, the days-to-cover ratio is currently 0.1 days.

Genprex Price Performance

Shares of Genprex stock traded down $0.02 on Monday, reaching $0.23. 427,508 shares of the company’s stock were exchanged, compared to its average volume of 3,454,850. Genprex has a 52 week low of $0.22 and a 52 week high of $4.09. The firm’s 50-day moving average is $0.34 and its two-hundred day moving average is $0.80.

Institutional Trading of Genprex

An institutional investor recently raised its position in Genprex stock. Virtu Financial LLC grew its holdings in shares of Genprex, Inc. (NASDAQ:GNPX) by 64.1% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 80,424 shares of the company’s stock after purchasing an additional 31,400 shares during the quarter. Virtu Financial LLC owned about 0.95% of Genprex worth $68,000 at the end of the most recent reporting period. Institutional investors own 14.05% of the company’s stock.

Genprex Company Profile

Genprex, Inc, a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes.